« Back to Farmacia Journal 4/2023

EFFECT OF MITOMYCIN C 0.02% ON ENDOTHELIAL CELLS DURING STREAMLIGHT TransPRK FOR PATIENTS WITH LOW- MODERATE MYOPIA/ASTIGMATISM

GEORGE SIMA 1, VALERIA MOCANU 1, ALEXANDRA MARIA PREDA 1, CATALINA TATARU 2*, CRISTINA PATRICIA PAC 1, MIHNEA MUNTEANU 1

Download Full Article PDF

Mitomycin C is an antimetabolite with an important anti-mitotic effect on cellular proliferation, also used as adjunctive therapy for haze prophylaxis after corneal surface ablation techniques. In this study, 60 eyes undergoing refractive surgery (Streamlight TransPRK) were allocated randomly into two groups of 30 eyes each: Group I: without the use of Mitomycin C 0.02% (MMC) and Group II: with intraoperative MMC 0.02% use for 20 seconds. Refractive results, efficacy, safety and endothelial layer function and morphology were evaluated during the three-month follow-up. The main outcome measures were endothelial cell density (ECD), coefficient of variation (CV), central corneal thickness (CCT), hexagonal cell percentage (HEX), uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA) and mean refractive spherical equivalent (MRSE). The assessments were compared between groups. After three months, the mean ECD decreased in both groups, the morphology and distribution of endothelial cells suffered modifications in both groups, with statistically insignificant differences between groups. In conclusion, intraoperative topical application of 0.1 mL of a 0.02% solution of mitomycin C on patients with low to moderate myopia with or without astigmatism undergoing Streamlight TransPRK does not have a negative impact on endothelial cell layer function or morphology.